

SIGNAL - Cohort of Breast Cancer Patients. Identification of Genetic Determinants that Influence Resistance/Sensitivity and/or Toxicity to Adjuvant Cancer Treatment and Genetic Determinants for Developing Breast Cancer.

Head :Pauporté Iris

Pivot Xavier

Cox David

Deleuze Jean-François

Blanché-Koch Hélène

Last update : 06/20/2016 | Version : 1 | ID : 73302

General

Identification

Detailed name Cohort of Breast Cancer Patients. Identification of Genetic Determinants that Influence Resistance/Sensitivity and/or Toxicity to Adjuvant Cancer Treatment and Genetic Determinants for Developing Breast Cancer.

Sign or acronym SIGNAL

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CCP 28/01/2009; ANSM: B881131-60

General Aspects

Medical area Cancer research

Pathology (details) Breast cancer

Health determinants Genetic
Healthcare system and access to health care services
Iatrogenic
Medicine

Keywords genetic determinant, breast, cancer, treatment

Scientific investigator(s) (Contact)

Name of the director Pauporté

Surname Iris

Address INSTITUT NATIONAL DU CANCER
52 AVENUE MORIZET
92513 BOULOGNE-BILLANCOURT

Phone +33 (0)1.41.10.14.86

Email ipauporte@institutcancer.fr

Organization National Cancer Institute

Name of the director Pivot

Surname Xavier

Phone +33 (0)3 81 66 93 86

Email Xavier.pivot@univ-fcomte.fr

Organization Besançon University Hospital

Name of the director Cox

Surname David

Phone +33 (0)4 78 78 59 12

Email david.cox@inserm.fr

Organization Lyon Cancer Research Centre

Name of the director Deleuze

Surname Jean-François

Email deleuze@cng.fr

Organization Fondation Jean Dausset-CEPH & National
Genotyping Centre

Name of the director Blanché-Koch

Surname Hélène

Phone +33 (0)1 53 72 50 42

Email blanche@cephb.fr

Organization Fondation Jean Dausset-CEPH

Collaborations

Participation in projects, Yes

networks and consortia

Details	ICGC (International Consortium of Genomics of Cancer)
---------	---

Funding

Funding status	Public
----------------	--------

Details	National Cancer Institute
---------	---------------------------

Governance of the database

Sponsor(s) or organisation(s) responsible	Institut National du Cancer
---	-----------------------------

Organisation status	Public
---------------------	--------

Presence of scientific or steering committees	Yes
---	-----

Additional contact

Main features

Type of database

Type of database	Study databases
------------------	-----------------

Study databases (details)	Cohort study
---------------------------	--------------

Database recruitment is carried out by an intermediary	A selection of health institutions and services
--	---

Database recruitment is made on the basis of:	Medication(s) taken
---	---------------------

Database recruitment is carried out as part of an interventional study	Yes
--	-----

Details	Performed at individual level
---------	-------------------------------

Additional information regarding sample selection.	Enrolment in healthcare facilities authorised to carry out cancer research. The physicians in charge of patient enrolment in the SIGNAL clinical trial offer breast cancer patients with overexpression or non-overexpression of the HER2 receptor the opportunity to participate in this genetic study. 3 groups are formed: Group HER2+: The HER2+ group will be made up of breast cancer patients with HER2 receptor
--	--

overexpression, treated with Trastuzumab and who agreed to participate in the study. Patients treated with Trastuzumab as part of a clinical trial (e.g. PHARE) are eligible for the SIGNAL trial.

Group HER2-: The HER2- group will be made up of breast cancer patients with non-overexpression of the HER2 receptor who agreed to participate in the study.

Healthy Control subjects: Recruited from other cohorts.

Database objective

Main objective

The aims of this study are:

- ? to identify determinants that influence resistance or sensitivity following adjuvant treatment with Herceptin®;
- ? to identify determinants of cardiac toxicity following adjuvant treatment with Herceptin®;
- ? to identify genetic determinants for developing different types of breast cancer: HER2+, triple negative, RH+;
- ? to identify genetic determinants for developing breast cancer.

Inclusion criteria

1. Women over 18 years old.
2. Histologically confirmed, non-metastatic, operable breast adenocarcinoma.
3. HER2+ tumour: all patients undergoing adjuvant treatment with Trastuzumab.
4. Signed informed consent.

Population type

Age

Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)

Population covered

Sick population

Gender

Woman

Geography area

National

Detail of the geography area

France

Data collection

Dates

Date of first collection (YYYY or YYYY-MM) 2009

MM/YYYY)

Date of last collection (YYYY or MM/YYYY) 2017

Size of the database

Size of the database (number of individuals) [1000-10 000[individuals

Details of the number of individuals 9,600

Data

Database activity Current data collection

Type of data collected
Clinical data
Declarative data
Paraclinical data
Biological data

Clinical data (detail) Direct physical measures
Medical registration

Details of collected clinical data Type of treatment received; breast cancer subtype; clinical events (relapse, death); heart monitoring.

Declarative data (detail) Paper self-questionnaire

Details of collected declarative data Physical attributes; reproductive history; family history; personal medical history; family records; physical activity; exposure to tobacco and alcohol; exposure to radiation.

Paraclinical data (detail) Mammography; CA15-3 (optional)

Biological data (detail) Blood; tumour sample

Presence of a biobank Yes

Contents of biobank
Whole blood
Plasma
Tissues
Cell lines
DNA

Details of biobank content DNA; plasma

Health parameters studied
Health event/morbidity
Health event/mortality
Health care consumption and services

Care consumption (detail)	Medicines consumption
Procedures	
Data collection method	By participating physicians and study investigators
Quality procedure(s) used	Implemented by independent operators
Participant monitoring	Yes
Monitoring procedures	Monitoring by convocation of the participant
Details on monitoring of participants	Patients will be monitored for 5 years by: ? clinical examination every 6 months ? CA15-3 every 6 months (optional) ? annual mammogram
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Presence of document that lists variables and coding procedures	Yes
Terms of data access (charter for data provision, format of data, availability delay)	Fully anonymised clinical data (no initials or order number; returned to correlation table; no date of birth; no reference to the healthcare centre or investigator that enrolled the patient) may be made readily available to third parties; please contact those in charge of the study. Requesting parties undertake to reference the study and its sponsor in all publications resulting from these data.
Access to aggregated data	Free access
Access to individual data	Free access